drugset

drugset / Trial / NCT03335553

A Study of Experimental Medication BMS-986235 in Healthy Subjects

NCT03335553 ↗

Phase 1 Completed 122 enrolled Bristol-Myers Squibb

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a study of experimental medication BMS-986235 in healthy subjects.

Timeline

Start: 2017-11-15
Primary completion: 2021-07-02
Completion: 2021-07-02

Publications

Singh J, Jackson KL, Fang H, Gumanti A, Claridge B, Tang FS, Kiriazis H, Salimova E, Parker AM, Nowell C, Woodman OL, Greening DW, Ritchie RH, Head GA, Qin CX. Novel formylpeptide receptor 1/2 agonist limits hypertension-induced cardiovascular damage. Cardiovasc Res. 2024 Sep 21;120(11):1336-1350. doi: 10.1093/cvr/cvae103.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	BMS-986235	Small molecule	—	Oral

Indications

No indication recorded.